cyclic undecapeptide immunosuppressant
Ciclosporin
Answer
Ciclosporin is authorised or registered in the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 9 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 1,328 registered trials, 143 of them running. Brand names on the FDA label register: Vevye, Cyclosporine, Cyclosporine Modified and Verkazia.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
1,328 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 10 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 935 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA label, application not recorded | FDA, openfda | 2026-08-31 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Ciclosporin changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 1,328 trials
| 2022-501677-39-00 | A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of
Conversion of Existing Adolescent R no status recorded · register updated 2026-09-25 |
|---|---|
| NCT01135641 | Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Ritux completed · register updated 2026-09-14 |
| NCT05153070 | Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes currently recruiting participants · register updated 2026-09-09 |
| NCT07774325 | A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood currently recruiting participants · register updated 2026-09-09 |
| 2023-504159-29-01 | Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation no status recorded · register updated 2026-08-27 |
| NCT00977977 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy currently recruiting participants · register updated 2026-08-27 |
| NCT06821542 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least running, but no longer enrolling · register updated 2026-08-25 |
| NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease Afte currently recruiting participants · register updated 2026-08-25 |
| NCT07773740 | Autologous Plasma Rich in Growth Factors for Severe Dry Eye Disease not yet recruiting participants · register updated 2026-08-25 |
| 2025-524312-11-00 | Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, p no status recorded · register updated 2026-08-19 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.